Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipotecan CCRT in HCC with PVTT
NCT03035006Phase 2Terminated
- Sponsor
- Taiwan Liposome Company
- Start
- Apr 2017
- Primary completion
- Oct 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lipotecan in hepatocellular carcinoma (HCC), portal vein tumor thrombosis (PVTT), sponsored by Taiwan Liposome Company. Started Apr 2017; status: terminated.
02
Drugs
lipotecan
03
Conditions
hepatocellular carcinoma (HCC)portal vein tumor thrombosis (PVTT)
Beyond the preview
Go deeper on NCT03035006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035006.